Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder

Boadie W. Dunlop, Steven P. Cole, Charles Nemeroff, Helen S. Mayberg, W. Edward Craighead

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Major depressive disorder (MDD) is a heterogeneous condition and individual patients are likely to be differentially responsive to specific treatments. In an exploratory factor analysis of three rating scales, the Genome-based Therapeutic Drugs for Depression (GENDEP) trial identified three factors that were differentially associated with outcome to nortriptyline and escitalopram. However, this factor analysis has neither been replicated or applied to a psychotherapy treatment. Methods We replicated the GENDEP analytic method in the Emory Predictors of Remission to Individual and Combined Treatments (PReDICT) study. The 17-item Hamilton Depression Rating Scale, Montgomery Asberg Depression Rating Scale, and Beck Depression Inventory were administered to 306 MDD patients in the PReDICT study, which randomized previously untreated adults to 12 weeks of treatment with cognitive behavior therapy (CBT), escitalopram, or duloxetine. Utilizing Item Response Theory methodologies, factor scores were derived from the three scales and the efficacy of the three treatments was compared for the identified factor scores. Results Four factors were identified: “Despair,” “Mood and Interest,” “Sleep,” and “Appetite.” These factors closely aligned with the factors identified in GENDEP. Compared to CBT, escitalopram and duloxetine produced more rapid but ultimately similar improvement on the Despair and Mood and Interest factors; no significant differences between treatments emerged on the other factors. Limitations The scales contained differing numbers of items pertaining to specific depressive symptoms. Conclusion The heterogeneity of MDD can be parsed into a consistent factor structure, with the factors showing differential rapidity, but ultimately similar, improvement across treatments.

Original languageEnglish (US)
Pages (from-to)111-119
Number of pages9
JournalJournal of Affective Disorders
Volume229
DOIs
StatePublished - Mar 15 2018

Fingerprint

Major Depressive Disorder
Cognitive Therapy
Antidepressive Agents
Depression
Citalopram
Therapeutics
Statistical Factor Analysis
Nortriptyline
Appetite
Psychotherapy
Sleep
Genome
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Biomarker
  • Duloxetine
  • Escitalopram
  • Item response theory
  • Precision medicine
  • Psychotherapy
  • Rating scales

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder. / Dunlop, Boadie W.; Cole, Steven P.; Nemeroff, Charles; Mayberg, Helen S.; Craighead, W. Edward.

In: Journal of Affective Disorders, Vol. 229, 15.03.2018, p. 111-119.

Research output: Contribution to journalArticle

@article{285581a4c773429d9f936626f741e965,
title = "Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder",
abstract = "Background Major depressive disorder (MDD) is a heterogeneous condition and individual patients are likely to be differentially responsive to specific treatments. In an exploratory factor analysis of three rating scales, the Genome-based Therapeutic Drugs for Depression (GENDEP) trial identified three factors that were differentially associated with outcome to nortriptyline and escitalopram. However, this factor analysis has neither been replicated or applied to a psychotherapy treatment. Methods We replicated the GENDEP analytic method in the Emory Predictors of Remission to Individual and Combined Treatments (PReDICT) study. The 17-item Hamilton Depression Rating Scale, Montgomery Asberg Depression Rating Scale, and Beck Depression Inventory were administered to 306 MDD patients in the PReDICT study, which randomized previously untreated adults to 12 weeks of treatment with cognitive behavior therapy (CBT), escitalopram, or duloxetine. Utilizing Item Response Theory methodologies, factor scores were derived from the three scales and the efficacy of the three treatments was compared for the identified factor scores. Results Four factors were identified: “Despair,” “Mood and Interest,” “Sleep,” and “Appetite.” These factors closely aligned with the factors identified in GENDEP. Compared to CBT, escitalopram and duloxetine produced more rapid but ultimately similar improvement on the Despair and Mood and Interest factors; no significant differences between treatments emerged on the other factors. Limitations The scales contained differing numbers of items pertaining to specific depressive symptoms. Conclusion The heterogeneity of MDD can be parsed into a consistent factor structure, with the factors showing differential rapidity, but ultimately similar, improvement across treatments.",
keywords = "Biomarker, Duloxetine, Escitalopram, Item response theory, Precision medicine, Psychotherapy, Rating scales",
author = "Dunlop, {Boadie W.} and Cole, {Steven P.} and Charles Nemeroff and Mayberg, {Helen S.} and Craighead, {W. Edward}",
year = "2018",
month = "3",
day = "15",
doi = "10.1016/j.jad.2017.12.035",
language = "English (US)",
volume = "229",
pages = "111--119",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",

}

TY - JOUR

T1 - Differential change on depressive symptom factors with antidepressant medication and cognitive behavior therapy for major depressive disorder

AU - Dunlop, Boadie W.

AU - Cole, Steven P.

AU - Nemeroff, Charles

AU - Mayberg, Helen S.

AU - Craighead, W. Edward

PY - 2018/3/15

Y1 - 2018/3/15

N2 - Background Major depressive disorder (MDD) is a heterogeneous condition and individual patients are likely to be differentially responsive to specific treatments. In an exploratory factor analysis of three rating scales, the Genome-based Therapeutic Drugs for Depression (GENDEP) trial identified three factors that were differentially associated with outcome to nortriptyline and escitalopram. However, this factor analysis has neither been replicated or applied to a psychotherapy treatment. Methods We replicated the GENDEP analytic method in the Emory Predictors of Remission to Individual and Combined Treatments (PReDICT) study. The 17-item Hamilton Depression Rating Scale, Montgomery Asberg Depression Rating Scale, and Beck Depression Inventory were administered to 306 MDD patients in the PReDICT study, which randomized previously untreated adults to 12 weeks of treatment with cognitive behavior therapy (CBT), escitalopram, or duloxetine. Utilizing Item Response Theory methodologies, factor scores were derived from the three scales and the efficacy of the three treatments was compared for the identified factor scores. Results Four factors were identified: “Despair,” “Mood and Interest,” “Sleep,” and “Appetite.” These factors closely aligned with the factors identified in GENDEP. Compared to CBT, escitalopram and duloxetine produced more rapid but ultimately similar improvement on the Despair and Mood and Interest factors; no significant differences between treatments emerged on the other factors. Limitations The scales contained differing numbers of items pertaining to specific depressive symptoms. Conclusion The heterogeneity of MDD can be parsed into a consistent factor structure, with the factors showing differential rapidity, but ultimately similar, improvement across treatments.

AB - Background Major depressive disorder (MDD) is a heterogeneous condition and individual patients are likely to be differentially responsive to specific treatments. In an exploratory factor analysis of three rating scales, the Genome-based Therapeutic Drugs for Depression (GENDEP) trial identified three factors that were differentially associated with outcome to nortriptyline and escitalopram. However, this factor analysis has neither been replicated or applied to a psychotherapy treatment. Methods We replicated the GENDEP analytic method in the Emory Predictors of Remission to Individual and Combined Treatments (PReDICT) study. The 17-item Hamilton Depression Rating Scale, Montgomery Asberg Depression Rating Scale, and Beck Depression Inventory were administered to 306 MDD patients in the PReDICT study, which randomized previously untreated adults to 12 weeks of treatment with cognitive behavior therapy (CBT), escitalopram, or duloxetine. Utilizing Item Response Theory methodologies, factor scores were derived from the three scales and the efficacy of the three treatments was compared for the identified factor scores. Results Four factors were identified: “Despair,” “Mood and Interest,” “Sleep,” and “Appetite.” These factors closely aligned with the factors identified in GENDEP. Compared to CBT, escitalopram and duloxetine produced more rapid but ultimately similar improvement on the Despair and Mood and Interest factors; no significant differences between treatments emerged on the other factors. Limitations The scales contained differing numbers of items pertaining to specific depressive symptoms. Conclusion The heterogeneity of MDD can be parsed into a consistent factor structure, with the factors showing differential rapidity, but ultimately similar, improvement across treatments.

KW - Biomarker

KW - Duloxetine

KW - Escitalopram

KW - Item response theory

KW - Precision medicine

KW - Psychotherapy

KW - Rating scales

UR - http://www.scopus.com/inward/record.url?scp=85039986235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039986235&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2017.12.035

DO - 10.1016/j.jad.2017.12.035

M3 - Article

VL - 229

SP - 111

EP - 119

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

ER -